rank-sum or the Kruskal-Wallis test as appropriate. The study was approved by the McGill University Health Centre research ethics board.
Results | Our CTU admits acutely ill patients who do not require surgery, chemotherapy, or immediate critical care. Top admitting diagnoses are pneumonia, congestive heart failure, and acute kidney injury. Approximately 45% and 10% of patients older than 65 years receive more than 10 or Discussion | In our single-center study of 1001 older medical inpatients, quetiapine was given to 1 in 8 patients (13.0%) with nearly two-thirds of the use being for sleep. About half of this use was continued at discharge (5.9%) including 1 in 7 patients who were first introduced to the medication as a sleep aid while in hospital. The proportion of patients who received quetiapine off-label for sleep was similar to that in a recent study of outpatients who received quetiapine for any off-label indication (66% vs 67%; P = .41). 3 There is a limited number of studies examining off-label quetiapine use and adverse drug events, 2 but associations with anticholinergic events and urinary tract symptoms are described in older adults with dementia, and sedation, fatigue, weight gain, and extrapyramidal symptoms in users irrespective of age. 4 Hospitalized and acutely ill older adults may be particularly susceptible to the neurocognitive adverse effects. Our study has limitations; first, our single academic center experience may not be generalizable to nonacademic centers or outside of Quebec. Second, use for sleep may have been misclassified if delirium was not adequately recorded in the medical record; however, the separation of the doses suggests that we excluded much of the nonsleep use. Third, we were able to obtain prescribing but not dispensing information; therefore, some patients may not have received the drug.
These limitations aside, it is important to highlight the overall prevalence of quetiapine use, the frequency of offlabel use for sleep, and the continuation of the drug postdischarge given that off-label medication use is associated with higher adverse drug event rates. 5 In the absence of quality randomized clinical trials demonstrating efficacy and safety, we suggest limiting off-label quetiapine use, particularly in elderly hospitalized patients. 
Generic Drug Approvals Since the 1984 Hatch-Waxman Act
The Hatch-Waxman Act of 1984 catalyzed the generic drug market, which now constitutes over 85% of US prescriptions. 1 The number of generic alternatives to a brand-name drug affects prices; availability of at least 4 generic drugs has been associated with brand-name price reductions of approximately 60% when compared with fewer or no generics. [2] [3] [4] Recently, prices for several generic drugs have increased 100-fold or more, in part because of limited competition. 5 We characterized the number of generic versions for all brand-name drugs approved by the US Food and Drug Administration (FDA), along with associations between the number of generics and characteristics of brand-name drugs.
Methods | We used the Drugs@FDA database to identify novel therapeutics approved in tablet or capsule formulation between September 30, 1984, and January 11, 2016 , under a new drug application (NDA). We excluded combinations with non-novel therapeutics and drugs ineligible for generic competition, including those discontinued for safety or effectiveness reasons and those with existing FDA-registered patents or exclusivity, determined in January 2016. The following brand-name drug product characteristics were determined: market status (currently marketed vs discontinued for nonsafety and/or effectiveness-related reasons); approval year; FDA priority review status; orphan status for the first approved indication; and primary therapeutic area assigned using the World Health Organization Anatomical Therapeutic Classification system. We used the same database to identify FDA-approved abbreviated NDAs for generic versions of these drugs, as of January 11, 2016, matching on active ingredient and route of administration and selecting each generic manufacturer's first approved dosage. We determined the proportion of drugs with any generic drugs approved and with 4 or
